trending Market Intelligence /marketintelligence/en/news-insights/trending/tmhvtjo73b8hlkygssiqla2 content esgSubNav
In This List

Mallinckrodt opioid painkiller rejected by US FDA


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Mallinckrodt opioid painkiller rejected by US FDA

Mallinckrodt PLC's SpecGx LLC unit said the U.S. Food and Drug Administration rejected the company's application for opioid painkiller Roxicodone.

SpecGx, which operates the U.K. drugmaker's specialty generics business, received a complete response letter from the U.S. drug agency on the company's new drug application for the immediate-release reformulation of Roxicodone tablets.

The FDA provided guidance on areas of further evaluation necessary to resubmit the application for further review and potential approval of the medicine.

"We are evaluating the FDA's letter and will request a meeting in the coming weeks to discuss it further," said Matt Harbaugh, president of Mallinckrodt's specialty generics division.

Roxicodone, also known as oxycodone hydrochloride, is used to manage pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The drug was designed with properties to deter intravenous and intranasal abuse.

Mallinckrodt develops, makes and distributes specialty pharmaceutical products and therapies.